Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT04594642 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04594642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04594642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 2, 2021
Completion date
June 19, 2028
Enrollment
226 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non hodgkin lymphoma, diffuse large b cell lymphoma, follicular lymphoma, high-grade b-cell lymphoma